CTOs on the Move

Rodin Therapeutics

www.rodintherapeutics.com

 
Rodin Therapeutics is a Biotechnology company located in Cambridge, Massachusetts, United States.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Rodin Therapeutics raised $17.3M on 01/06/2016
Rodin Therapeutics raised $27M on 09/18/2017

Similar Companies

Tri-Source Pharma

Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.

Stoke Therapeutics

Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe #geneticdiseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. At Stoke, we believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or #TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. We have identified approximately 2,900 genetic diseases which we believe may be amenable to TANGO. At Stoke, we are united around a common goal: to improve the lives of people living with severe genetic diseases. Stoke is located in Bedford, MA with offices in Cambridge, MA.

Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow`s industrial biosolutions, improving our customers' business and the use of our planet`s resources.

Spaltudaq Corporation

Spaltudaq Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axovant

Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.